Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Aufreinigung
This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Immunogen
This ATG4C antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 419-448 amino acids from the C-terminal region of human ATG4C.
ATG4C
Reaktivität: Human
WB, IF, ICC
Wirt: Kaninchen
Polyclonal
PerCP
Applikationshinweise
WB: 1:1000. IHC-P: 1:50~100
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Haltbarkeit
6 months
Ma, Panda, Lin: "Temporal orchestration of circadian autophagy rhythm by C/EBP?." in: The EMBO journal, Vol. 30, Issue 22, pp. 4642-51, (2012) (PubMed).
Norman, Cohen, Bampton: "The in vitro cleavage of the hAtg proteins by cell death proteases." in: Autophagy, Vol. 6, Issue 8, pp. 1042-56, (2010) (PubMed).
Shintani, Klionsky: "Autophagy in health and disease: a double-edged sword." in: Science (New York, N.Y.), Vol. 306, Issue 5698, pp. 990-5, (2004) (PubMed).
Target
ATG4C
(Autophagy related 4C Cysteine Peptidase (ATG4C))
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). APG4 is a cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes.